A Phase 4 interventional study of Oracea in Papulopustular Rosacea, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 25 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-08-23.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing doxycycline in Rosacea — none open to participants now, 1 under way, none of them phase 3. Doxycycline · Rosacea.
Among the 12 studies testing doxycycline in Rosacea, this one is the 11th largest by enrollment, is the only one that started in 2013, is one of 6 in phase 4, and was the 7th registered.
233 studies on the registry are indexed under Rosacea; 22 are open to participants now.
Browse Rosacea studies →None of the 12 studies testing doxycycline in Rosacea is open now. The open studies under Rosacea, anywhere →
Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 25 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2013.
This study's enrollment of 24 is below the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 150 across the 12 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 7 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
28 studies in Rosacea by Galderma Group AG: none open now, none under way, none of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 28 studies in Rosacea by Galderma Group AG, this one is the 23rd largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2013, is one of 9 in phase 4, and was the 20th registered.
Galderma Group AG’s Rosacea studies by the year they started, since 2002.
1 of the studies testing doxycycline in Rosacea that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04108897Johns Hopkins UniversityAnalysis of the Microbiome in Rosacea | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing doxycycline in Rosacea, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 28 in Rosacea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oracea (doxycycline USP, 40mg\[30mg immediate release/ 10mg delayed release beads\] taken once daily in the morning on an empty stomach, one hour before meals or two hours after. Oral dose for 12 weeks
Drug: Oracea
Also known as: doxycycline USP, 40 mg (30 mg immediate release/ 10 mg delayed release beads)
Rosacea Score on the Visual Analog Scale
VAS = visual analog scale, 10 cm scale in which 0 = no rosacea, 10 = worst rosacea imaginable
Time frame: Baseline, Weeks 2, 6, and 12
Rosacea-Specific Quality of Life Index
ROSACEA-SPECIFIC QUALITY OF LIFE INDEX©: average of scores to 22 questions on a 5 point scale (1 = never, 5 = all the time)
Time frame: Baseline, Weeks 2, 6, and 12
Patient Global Assessment (PGA) of Rosacea Scores
Patient Global Assessment (PGA) of Rosacea: 0 = clear, no signs or symptoms present; 1 = Near clear, 1 or 2 papules; 2 = mild, some (3 to 10) papules/pustules; 3 = moderate, moderate (11 to 19) number of papules and pustules; 4 = severe, numerous (≥ 20) papules/pustules; nodules
Time frame: Baseline, Weeks 2, 6, and 12
Patient Satisfaction Question
The patient satisfaction question was answered by the subject at week 2, week 6, and week 12. The subject was asked how satisfied they were with this treatment (doxycycline MR) for rosacea.
Time frame: Week 2, 6, and 12
| Milestone | Oracea |
|---|---|
| Started | 24 |
| Completed | 20 |
| Not completed | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 2 |
VAS = visual analog scale, 10 cm scale in which 0 = no rosacea, 10 = worst rosacea imaginable
| units on a scale | Oracea |
|---|---|
| Baseline | 4.50 ± 1.81 |
| Week 2 | 4.52 ± 1.87 |
| Week 6 | 3.77 ± 1.93 |
| Week 12 | 3.06 ± 2.34 |
ROSACEA-SPECIFIC QUALITY OF LIFE INDEX©: average of scores to 22 questions on a 5 point scale (1 = never, 5 = all the time)
| units on a scale | Oracea |
|---|---|
| Baseline | 3.34 ± 0.55 |
| Week 2 | 3.07 ± 0.56 |
| Week 6 | 2.89 ± 0.81 |
| Week 12 | 2.85 ± 0.86 |
Patient Global Assessment (PGA) of Rosacea: 0 = clear, no signs or symptoms present; 1 = Near clear, 1 or 2 papules; 2 = mild, some (3 to 10) papules/pustules; 3 = moderate, moderate (11 to 19) number of papules and pustules; 4 = severe, numerous (≥ 20) papules/pustules; nodules
| participants | 0 = Clear | 1 = Near Clear | 2 = Mild | 3 = Moderate | 4 = Severe |
|---|---|---|---|---|---|
| Baseline | 0 | 1 | 17 | 4 | 0 |
| Week 2 | 0 | 4 | 16 | 2 | 0 |
| Week 6 | 0 | 10 | 11 | 1 | 0 |
| Week 12 | 3 | 14 | 4 | 1 | 0 |
The patient satisfaction question was answered by the subject at week 2, week 6, and week 12. The subject was asked how satisfied they were with this treatment (doxycycline MR) for rosacea.
| participants | Very Satisfied | Satisfied | Neither Satisfied Nor Dissatisfied | Dissatisfied | Very Dissatisfied |
|---|---|---|---|---|---|
| Week 2 | 1 | 11 | 8 | 2 | 0 |
| Week 6 | 4 | 7 | 8 | 2 | 1 |
| Week 12 | 8 | 6 | 5 | 2 | 1 |
Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oracea | — | 0/24 (0%) | 7/24 (29.2%) |
| Event | Oracea |
|---|---|
| VomitingGastrointestinal disorders | 3/24 |
| DiarrheaGastrointestinal disorders | 2/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/24 |
Safety population
| Age, Continuous(years) | Oracea |
|---|---|
| Mean | 53.04 ± 11.02 |
| Sex: Female, Male(Participants) | Oracea |
|---|---|
| Female | 1 |
| Male | 23 |
| Ethnicity (NIH/OMB)(Participants) | Oracea |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 21 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Oracea |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 24 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Years since the first rosacea diagnosis(years) | Oracea |
|---|---|
| Mean | 5.75 ± 8.36 |
| Skin type(participants) | Oracea |
|---|---|
| Dry | 8 |
| Normal | 4 |
| Oily | 1 |
| Combination | 11 |
| Fistzpatrick Skin Type(participants) | Oracea |
|---|---|
| I | 2 |
| II | 15 |
| III | 5 |
| IV | 2 |
| V | 0 |
| VI | 0 |
The record gives a start of Mar 2013, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxycycline